ASCO 2022 Conference Coverage
Playback speed
10 seconds
Lecture Summary - ASCO 2022 Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in HER2+ Unresectable and/or Metastatic Breast Cancer: Safety Follow-Up of the Phase 3 DESTINY-Breast03
By
ASCO 2022 Conference Coverage
FEATURING
Erika Hamilton
By
ASCO 2022 Conference Coverage
FEATURING
Erika Hamilton
405 views
June 13, 2022
Login to view comments.
Click here to Login
Breast